Lorigerlimab (MGD019) in Patients With Pancreatic Adenocarcinoma and Homologous Recombination Deficiency

NCT07565155 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Adenocarcinoma
Homologous Recombination Deficiency

Interventions

DRUG: Lorigerlimab

Sponsor

Peter Hosein, MD

Collaborators

[object Object]